- Home
- JANX vs OCSL Comparison
JANX vs OCSL Comparison
Compare JANX & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- OCSL
- Stock Information
- Founded
- JANX 2017
- OCSL 2007
- Country
- JANX United States
- OCSL United States
- Employees
- JANX N/A
- OCSL N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- OCSL Finance: Consumer Services
- Sector
- JANX Health Care
- OCSL Finance
- Exchange
- JANX Nasdaq
- OCSL Nasdaq
- Market Cap
- JANX 1.4B
- OCSL 1.2B
- IPO Year
- JANX 2021
- OCSL 2008
- Fundamental
- Price
- JANX $24.87
- OCSL $13.51
- Analyst Decision
- JANX Strong Buy
- OCSL Hold
- Analyst Count
- JANX 8
- OCSL 6
- Target Price
- JANX $90.63
- OCSL $15.20
- AVG Volume (30 Days)
- JANX 892.8K
- OCSL 635.0K
- Earning Date
- JANX 08-07-2025
- OCSL 08-05-2025
- Dividend Yield
- JANX N/A
- OCSL 11.78%
- EPS Growth
- JANX N/A
- OCSL N/A
- EPS
- JANX N/A
- OCSL 0.55
- Revenue
- JANX $439,000.00
- OCSL $334,099,000.00
- Revenue This Year
- JANX N/A
- OCSL N/A
- Revenue Next Year
- JANX $1,470.83
- OCSL N/A
- P/E Ratio
- JANX N/A
- OCSL $24.85
- Revenue Growth
- JANX N/A
- OCSL N/A
- 52 Week Low
- JANX $21.97
- OCSL $12.50
- 52 Week High
- JANX $71.71
- OCSL $17.16
- Technical
- Relative Strength Index (RSI)
- JANX 51.13
- OCSL 43.59
- Support Level
- JANX $23.96
- OCSL $13.52
- Resistance Level
- JANX $25.93
- OCSL $13.55
- Average True Range (ATR)
- JANX 1.55
- OCSL 0.25
- MACD
- JANX 0.06
- OCSL -0.00
- Stochastic Oscillator
- JANX 61.91
- OCSL 53.96
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.